Rx Propellant appoints Ashish Singh as its CEO & MD

New Delhi: Rx Propellant, India’s leading science and R&D infrastructure platform established by Actis, and part of General Atlantic, a global investment leader, has appointed Ashish Singh as its Chief Executive Officer and Managing Director.

Ashish assumed the role a few months earlier and has been leading the company’s next phase of growth, as it builds institutional-grade laboratory infrastructure across India’s key sciences clusters.

Ashish transitions into a full-time executive leadership role from Actis, where he previously served as the Head of Actis’ real estate investments in India and Southeast Asia. During his tenure at Actis, Ashish played a central role in the creation, strategic direction and growth of Rx Propellant, working closely with the platform to position it as India’s most credible science infrastructure builder-operator.

With over three decades of experience across real estate, investment management and business consulting, Ashish has successfully built and scaled institutional platforms across emerging asset classes. Prior to Actis, he held senior leadership roles at global firms including Standard Chartered Bank, Tishman Speyer and Cushman & Wakefield, where he advised and invested across traditional as well as new-economy real estate sectors.

His appointment reflects Actis’ long-term conviction in Rx Propellant and underscores a deliberate shift toward strengthening execution, scale and leadership depth as the company chalks out an ambitious growth plan and expands its footprint.

Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said: “Ashish has been deeply involved in shaping Rx Propellant since its formation and brings a rare combination of investment discipline, operating perspective and long-term vision. As the platform enters its next phase of growth, his leadership will be instrumental in building Rx Propellant into a market-defining institution for strategic science infrastructure solutions in India.”

Commenting on his appointment, Ashish Singh, CEO & Managing Director, Rx Propellant, said: “Rx Propellant has built a strong foundation anchored in sector expertise, design, sustainability and execution at scale. I look forward to working closely with our teams and partners to deepen our presence across key clusters, deliver globally benchmarked campuses, and build a platform that supports innovation and long-term value creation.”

Under Ashish’s leadership, Rx Propellant will continue to focus on developing large-format sustainable campuses, designed to support R&D, innovation and scale-up for global and Indian companies engaged in science and R&D.

Rx Propellant currently has a development portfolio of around 4 million square feet across Hyderabad and Navi Mumbai, and a strong pipeline of future expansion. The company continues to partner with leading pharmaceutical, biotechnology and research-led organisations seeking high-quality, scalable laboratory environments aligned with global standards.